Cantor Fitzgerald Weighs in on Reata Pharmaceuticals, Inc s FY2023 Earnings (NASDAQ:RETA) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Reata Pharmaceuticals (NASDAQ:RETA – Get Free Report)‘s stock had its “neutral” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $172.00 price target on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 1.73% from the company’s previous close. […]
Barclays lowered shares of Reata Pharmaceuticals (NASDAQ:RETA – Free Report) from an overweight rating to an equal weight rating in a research note issued to investors on Tuesday, MarketBeat reports. The brokerage currently has $172.00 price target on the stock, up from their prior price target of $110.00. Several other research analysts also recently weighed […]
Reata Pharmaceuticals (NASDAQ:RETA) Downgraded to Neutral at LADENBURG THALM/SH SH kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
Citigroup cut shares of Reata Pharmaceuticals (NASDAQ:RETA – Free Report) from a buy rating to a neutral rating in a research report released on Tuesday morning, Marketbeat reports. Citigroup currently has $172.50 target price on the stock, up from their prior target price of $127.00. Other equities analysts have also recently issued reports about the […]